YAP1 and neoplasm: The combination of the YAP/TAZ targeting agent, CA3, with lenvatinib in a subcutaneous model of a cell line derived from an extracranial site of a patient who developed rapid brain metastasis, slowed tumor growth and decreased VM density, providing pre-clinical rationale for future development of novel combination anti-vasculogenic therapies for these patients.